1. Home
  2. IMNN vs FRSX Comparison

IMNN vs FRSX Comparison

Compare IMNN & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$4.20

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Logo Foresight Autonomous Holdings Ltd.

FRSX

Foresight Autonomous Holdings Ltd.

HOLD

Current Price

$1.90

Market Cap

6.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNN
FRSX
Founded
1982
N/A
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
6.3M
IPO Year
1985
2017

Fundamental Metrics

Financial Performance
Metric
IMNN
FRSX
Price
$4.20
$1.90
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$182.61
N/A
AVG Volume (30 Days)
32.9K
562.5K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$452,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.56
$1.75
52 Week High
$41.22
$18.41

Technical Indicators

Market Signals
Indicator
IMNN
FRSX
Relative Strength Index (RSI) 52.07 38.12
Support Level $3.83 $1.76
Resistance Level $4.35 $1.88
Average True Range (ATR) 0.19 0.08
MACD 0.07 -0.02
Stochastic Oscillator 71.43 26.09

Price Performance

Historical Comparison
IMNN
FRSX

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: